During this segment, Raoul S. Concepcion, MD, explains how the rapid development of agents for castration-resistant prostate cancer (CRPC) has led to an expanding number of clinical guidelines, developed by multiple organizations, for clinicians’ use during important treatment-decisions.
However, he explains that the treatment options recommended in these guidelines are expensive, creating a challenge to both clinicians and payers.
To clarify misconceptions about medical policy and coverage for patients with CRPC, Michael Kolodziej, MD, discusses the variables that payers consider when making decisions about coverage for these expensive treatment options.
Reviving the Classics: The Role of Older Medications in Modern Dermatology
March 9th 2025Older, generic medications, including ones for cyclosporine, nicotinamide, and dapsone, can effectively treat patients with various dermatological conditions while helping to reduce insurance and cost barriers.
Read More
Demographic Disparities in Video Visit Telemetry: Understanding Telemedicine Utilization
March 7th 2025A stratified demographics analysis of video visit telemetry data reveals that age older than 65 years and African American/Black race are associated with higher video visit failure rates, whereas language, sex, and ethnicity are not.
Read More